Related Experiment Video

Updated: Jul 5, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Selective killing of Smad4-negative tumor cells via a designed repressor strategy

Vidula Dixit1, Rudy L Juliano

  • 1Department of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina 27599-7365, USA.

Molecular Pharmacology
|April 23, 2008
PubMed

Insights

Researchers developed a novel gene therapy to selectively kill Smad4-deficient pancreatic and colon tumor cells. This approach uses a suicide gene system that targets cells lacking the Smad4 tumor suppressor, offering a potential new cancer treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Smad4 is a critical tumor suppressor gene frequently inactivated in pancreatic and colon cancers.
  • Targeting Smad4-deficient tumors is a promising strategy for cancer therapy.

Purpose of the Study:

  • To develop a method for the selective elimination of Smad4-deficient tumor cells.
  • To investigate Smad4-responsive regulation of gene expression for targeted cancer therapy.

Main Methods:

  • Utilized a vector system with zinc finger binding domains and the herpes simplex virus thymidine kinase (HSV-TK) suicide gene.
  • Demonstrated Smad4-responsive regulation of HSV-TK expression and ganciclovir (GCV) toxicity.
  • Employed stable transfection in pancreatic tumor cells and adenoviral delivery in colon tumor cells.

Main Results:

  • Achieved differential HSV-TK expression and GCV toxicity based on Smad4 presence in pancreatic tumor cells.
  • Demonstrated preferential killing of Smad4-negative colon tumor cells using an adenoviral vector system.
  • Confirmed Smad4 status-dependent selective tumor cell killing.

Conclusions:

  • The developed vector system enables Smad4-responsive regulation of gene expression.
  • This approach allows for the selective killing of Smad4-deficient pancreatic and colon tumor cells.
  • Findings suggest a potential new therapeutic strategy for Smad4-associated cancers.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...